CT Vision (International) Holdings Limited
中天宏信(國際)控股有限公司
(formerly known as CT Vision S.L. (International) Holdings Limited)
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 994)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the "**Meeting**") of CT Vision (International) Holdings Limited (the "**Company**") will be held 2/F, A Plus, 35-45B Bonham Strand, Sheung Wan, Hong Kong, on Monday, 29 June 2026 at 10:15 a.m. (or immediately after the annual general meeting of the Company to be held on the same date, whichever is later) for considering and, if thought fit, passing, with or without amendments, the following resolutions of the Company:

ORDINARY RESOLUTION

1. "**THAT**:

   (a) subject to and conditional upon the Listing Committee of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") granting approval for the listing of, and permission to deal in, the shares of the Company (the "**Shares**") which may fall to be issued and allotted pursuant to the exercise of any options which may be granted under the new share option scheme of the Company (the "**New Share Option Scheme**"), the rules of which have been produced to the Meeting and marked "A" and initialed by the chairman of the Meeting for identification purpose, the rules of the New Share Option Scheme be and are hereby approved and adopted and the directors (the "**Directors**") of the Company be and are hereby authorised to grant options to allot, issue and deal in the Shares as may be required to be allotted and issued (and/or to transfer such number of treasury Shares, as applicable) upon the exercise of any option granted thereunder and to take all such steps and attend all such matters, approve and execute (whether under hand or under seal) such documents and do such other things, for and on behalf of the Company, as the Directors may consider necessary, desirable or expedient to effect and implement the New Share Option Scheme;

(b) (i) the total number of Shares to be allotted and issued or transferred out of treasury in respect of any options and awards granted under the New Share Option Scheme, the Share Award Scheme (defined as below) and any other share schemes of the Company as may from time to time be adopted by the Company, shall not in aggregate exceed 10% of total number of Shares in issue (excluding treasury Shares, if any) as at the date of approval of the New Share Option Scheme; and

(ii) the scheme mandate limit or the total number of Shares to be allotted and issued or transferred out of treasury upon exercise of the right attached to the options granted under the New Share Option Scheme and any other share option scheme shall not in aggregate exceed 5.0% (comprising the service provider sublimit as provided in the New Share Option Scheme) (the "**Scheme Mandate Limit (SOS)**") of the Shares in issue (excluding treasury Shares, if any) as at the date of approval of the New Share Option Scheme.

2. "**THAT** within the Scheme Mandate Limit (SOS), the service provider sublimit on the total number of Shares that may be allotted and issued or transferred out of treasury in respect of all options to be granted to service providers under the New Share Option Scheme and any other share option scheme be equal to 0.5% of the total number of Shares in issue (excluding treasury Shares, if any) on the date of approval of the New Share Option Scheme be and is hereby approved and adopted and the Directors be and are hereby authorised to take all such steps and attend all such matters, approve and execute (whether under hand or under seal) such documents and do such other things, for and on behalf of the Company, as the Directors may consider necessary, desirable or expedient to effect and implement the scheme mandate limit and service provider sublimit."

3. "**THAT** subject to the pass of resolution no. 1 above, the existing share option scheme of the Company adopted on 23 June 2017 be and is hereby canceled and terminated."

4. “**THAT**:

(a) subject to and conditional upon the Listing Committee of the Stock Exchange granting approval for the listing of, and permission to deal in, the Shares which may fall to be allotted and issued pursuant to the share award scheme of the Company (the “**Share Award Scheme**”), the rules of which have been produced to the Meeting and marked “B” and initialed by the chairman of the Meeting for identification purpose, the rules of the Share Award Scheme be and are hereby approved and adopted and the Directors, the remuneration committee of the Board and the delegate(s) of the aforementioned be and are hereby authorized to do all such acts and to enter into all such transactions, arrangements and agreements as may be necessary or expedient in order to give full effect to the Share Award Scheme;

(b) (i) the total number of Shares to be allotted and issued or transferred out of treasury in respect of any options and awards granted under the New Share Option Scheme, the Share Award Scheme and any other share schemes of the Company as may from time to time be adopted by the Company, shall not in aggregate exceed 10% of total number of Shares in issue (excluding treasury Shares, if any) as at the date of approval of the Share Award Scheme; and

(ii) the scheme mandate limit or the total number of Shares to be awarded or transferred out of treasury under the Share Award Scheme and any other share award scheme shall not in aggregate exceed 5.0% (comprising the service provider sublimit as provided in the Share Award Scheme) (the “**Scheme Mandate Limit (SAS)**”) of the Shares in issue (excluding treasury Shares, if any) as at the date of approval of the Share Award Scheme; and

5. “**THAT** within the Scheme Mandate Limit (SAS), the service provider sublimit on the total number of Shares that may be issued or transferred out of treasury in respect of all awards to be granted to service providers under the Share Award Schemes and any other share award scheme be equal to 0.5% of the total number of Shares in issue (excluding treasury Shares, if any) on the date of approval of the Share Award Scheme be and is hereby approved and adopted and the Directors be and are hereby authorised to take all such steps and attend all such matters, approve and execute (whether under hand or under seal) such documents and do such other things, for and on behalf of the Company, as the Directors may consider necessary, desirable or expedient to effect and implement the scheme mandate limit and service provider sublimit.”

Yours faithfully,
On behalf of the Board
CT Vision (International) Holdings Limited
Sun Dexin
Executive Director

Hong Kong, 12 June 2026

Notes:

1. Any member of the Company entitled to attend and vote at the Meeting shall be entitled to appoint another person as his/her proxy to attend and vote instead of him/her. A member who is the holder of two or more shares may appoint more than one proxy to represent him/her and vote on his/her behalf at the Meeting. A proxy need not be a member of the Company. On a poll, votes may be given either personally or by proxy.

2. The instrument appointing a proxy shall be in writing under the hand of the appointer or of his/her attorney duly authorised in writing or, if the appointer is a corporation, either under its seal or under the hand of an officer, attorney or other person authorised to sign the same.

3. To be valid, the instrument appointing a proxy and (if required by the Board) the power of attorney or other authority (if any) under which it is signed, or a notarially certified copy of such power or authority, shall be delivered to the Hong Kong branch share registrar and transfer office of the Company, Boardroom Share Registrars (HK) Limited at 2103B, 21/F, 148 Electric Road, North Point, Hong Kong as soon as possible and in any event not less than 48 hours (i.e. 10:15 a.m. on Saturday, 27 June 2026) before the time appointed for holding the Meeting or any adjournment thereof.

4. No instrument appointing a proxy shall be valid after expiration of 12 months from the date named in it as the date of its execution, except at an adjourned meeting or on a poll demanded at the Meeting or any adjournment thereof in cases where the Meeting was originally held within 12 months from such date.

5. Where there are joint holders of any shares, any one of such joint holders may vote at the Meeting, either in person or by proxy, in respect of such share as if he/she were solely entitled thereto, but if more than one of such joint holders be present at the Meeting, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders, and for this purpose, seniority shall be determined by the order in which the names stand in the Register of Members of the Company in respect of the joint holding.

6. Completion and delivery of an instrument appointing a proxy shall not preclude a member from attending and voting in person at the Meeting if the member so desire and in such event, the instrument appointing a proxy should be deemed to be revoked.

7. The record date for determining the entitlement of the Shareholders to attend and vote at the Meeting will be Monday, 29 June 2026. There will be no book close period in respect of the Meeting. In order to establish the right to attend and vote at the Meeting, all transfers, accompanied by the relevant share certificates, must be lodged with the Company's Hong Kong branch share registrar and transfer office, Boardroom Share Registrars (HK) Limited at 2103B, 21/F, 148 Electric Road, North Point, Hong Kong no later than 4:30 p.m. on Tuesday, 23 June 2026.

8. Details of the summary of the principal terms of the New Share Option Scheme and the Share Award Scheme are set out in Appendix I and Appendix II to the circular of the Company dated 12 June 2026 respectively.

As at the date of this notice, the Board comprises five executive Directors, namely Mr. Wu Rui, Mr. Guo Jianfeng, Mr. Ding Ji, Mr. Lian Mingcheng and Mr. Sun Dexin, one non-executive Director, namely Dr. Ho Chun Kit Gregory, and three independent non-executive Directors, namely Dr. Lin Tat Pang, Ms. Liu Zhen and Dr. Yang Sen.